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Abstract
Glioblastomas are the most frequent and aggressive intracranial neoplasms in humans, and despite advances and
the introduction of the alkylating agent temozolomide in therapy have improved patient survival, resistance
mechanisms limit benefits. Recent studies support that glioblastoma stem-like cells (GSCs), a cell subpopulation
within the tumour, are involved in the aberrant expansion and therapy resistance properties of glioblastomas, through
still unclear mechanisms. Emerging evidence suggests that sphingosine-1-phosphate (S1P) a potent onco-promoter
able to act as extracellular signal, favours malignant and chemoresistance properties in GSCs. Notwithstanding, the
origin of S1P in the GSC environment remains unknown. We investigated S1P metabolism, release, and role in cell
survival properties of GSCs isolated from either U87-MG cell line or a primary culture of human glioblastoma. We
show that both GSC models, grown as neurospheres and expressing GSC markers, are resistant to temozolomide,
despite not expressing the DNA repair protein MGMT, a major contributor to temozolomide-resistance. Pulse
experiments with labelled sphingosine revealed that both GSC types are able to rapidly phosphorylate the long-chain
base, and that the newly produced S1P is efficiently degraded. Of relevance, we found that S1P was present in GSC
extracellular medium, its level being significantly higher than in U87-MG cells, and that the extracellular/intracellular
ratio of S1P was about ten-fold higher in GSCs. The activity of sphingosine kinases was undetectable in GSC media,
suggesting that mechanisms of S1P transport to the extracellular environment are constitutive in GSCs. In addition
we found that an inhibitor of S1P biosynthesis made GSCs sensitive to temozolomide (TMZ), and that exogenous
S1P reverted this effect, thus involving extracellular S1P as a GSC survival signal in TMZ resistance. Altogether our
data implicate for the first time GSCs as a pivotal source of extracellular S1P, which might act as an autocrine/
paracrine signal contributing to their malignant properties.
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Introduction
Glioblastoma multiforme is the most frequent and aggressive
primary central nervous system tumor in humans, with one of
the worst survival rates of all the human cancers [1], due to a
high proliferation rate, migrating and invasive properties, and
resistance to current therapeutic intervention. Although the
introduction of the alkylating agent temozolomide (TMZ) in
glioblastoma therapy has improved patient survival, the
prognosis of patients remains unfavorable [2]. Recent studies
suggest that a subpopulation of cells, named glioblastoma
stem cells (GSCs), exists within the tumor, and plays a crucial
role in glioblastoma initiation, maintenance, and malignant
behavior [3,4]. Of relevance, GSCs possess the ability to
extensively self-renew and are capable of initiating the tumor
upon orthotopic transplantation, giving rise to a heterogeneous
population of cells such as those found in their parent tumors
[5,6]. In addition, GSCs are thought to be responsible for
maintaining these tumors after gross surgical resection and
therapy, and are resistant to radiations and different cytotoxic
drugs, including TMZ, the current mainstay of anti-glioma
chemotherapy [7]. In spite different aberrations in GSCs may
be involved in their intrinsic drug resistance [8–10], and the
expression of the DNA repair protein O6-methylguanine-DNA
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methyltransferase (MGMT) appears a key factor strictly
associated to their TMZ-resistance [11,12], our knowledge of
the mechanisms underlying malignant and chemoresistance
properties of GSCs remains limited. Thus, the molecular
characterization of GSCs represents a critical step in defining
glioblastoma properties, and may be essential in developing
effective therapeutic strategies.
An increasing number of evidence indicates that the
sphingoid molecule sphingosine-1-phosphate (S1P) is a potent
bioactive lipid able to regulate a spectrum of essential cellular
processes strictly related to cancer, such as proliferation,
invasivity, survival and angiogenesis [13,14]. S1P is an
intermediate of sphingolipid metabolism, and its cellular levels
are finely regulated through the modulation of different
enzymes responsible for its synthesis and degradation [15]. In
cells, S1P is formed from sphingosine (Sph) and ATP in a
reaction catalyzed by two isoenzymes, named sphingosine
kinase 1 (SK1) and 2 (SK2) [16]. Once formed, S1P can be
metabolized through two different pathways: the
dephosphorylation back to Sph, and the irreversible cleavage
to hexadecenal and phosphoethanolamine [17]. Accumulating
evidence demonstrates that S1P plays an important role in the
extracellular milieu, being secreted by some cell types,
especially blood cells, but also endothelial and mast cells [18].
Figure 1.  Characterization of cell models.  (A)
Representative images of U87-MG and U–SC morphology.
Images were viewed on a contrast phase microscope and
digital images were acquired (magnification, 10X; scale bar,
100 µm). (B) Expression of CD133 and nestin, assessed by
Real-Time PCR. Results are expressed as fold-change relative
to U87-MG. Values are the mean ± SD of three independent
experiments. * p < 0.05; ** p <0.01 vs U87-MG cells.
doi: 10.1371/journal.pone.0068229.g001
The finding that neurons and astrocytes can constitutively
export S1P supports that also cells of the nervous system can
be an origin of extracellular S1P [19,20]. Once released, S1P
can act in an autocrine/paracrine manner, through interaction
with specific transmembrane receptors (S1P1-5), coupled to
different G-proteins and displaying tissue-specific expression
patterns [21]. Through this interaction S1P can activate several
signal transduction pathways, and thus elicit a variety of cell-
specific responses controlling cell behaviour.
S1P has emerged as an onco-promoter molecule in different
tumors, including glioblastomas [18,22,23]. In fact, it has been
documented that S1P enhances proliferation, motility,
invasiveness, and malignant behavior of glioblastoma cells
[24,25]. In support to the importance of S1P in glioblastomas,
SK1 is elevated in glioblastoma cell lines [26,27], is up
regulated in glioma specimens in comparison with adjacent
normal tissue, and its expression level correlates with the
histological grade of the tumors and a poor patient survival
[28,29]. In addition, other recent studies showed that SK1
inhibition causes apoptosis in TMZ-resistant glioma cells [30],
and decreases growth and invasiveness of human GBM cells
and of GBM cell xenograft growth in mice [31]. A further
support to S1P as an important autocrine/paracrine messenger
in glioblastomas emerges from the evidence that some glioma
cell lines are able to release S1P in the extracellular milieu
[27,32]. Moreover, it has been extensively demonstrated that
glioblastoma cells commonly express different S1P receptors,
all contributing to glioblastoma cell growth and invasion through
distinct, but overlapping mechanisms [25,33,34].
Up to now, evidence on the role of S1P as an autocrine
and/or paracrine factor modulating GSCs properties is scarce.
Annabi and coworkers [35] reported that GSCs, isolated from a
glioblastoma cell line, express S1P receptors and that
exogenously added S1P promotes their migration and
invasivity. Furthermore, Mora and colleagues [36]
demonstrated that SK inhibition causes neurosphere
dissociation, abolishes their growth, and promotes cell death in
GSCs. Despite these studies suggest that S1P may act as an
important mediator of GSCs properties, the ability of GSCs to
produce and release S1P remains to be defined. Up to now, it
is not known if GSCs are able to release S1P, or other cells
within the tumor are the source of the extracellular S1P acting
on GSCs. On these premises, the aim of this study was to
investigate the ability of GSCs to produce and/or release S1P
in the extracellular milieu and the role of this sphingoid
molecule in GSC resistance to TMZ. By using GSCs derived
from a human glioblastoma cell line, as well as those isolated
from primary cultures of a human glioblastoma, this study
demonstrate that GSCs can rapidly synthesize S1P, and
efficiently release it extracellularly. In addition, we found that
extracellular S1P acts as autocrine/paracrine signal involved in
TMZ resistance, by acting as a survival molecule in GSCs.
Materials and Methods
Materials
All reagents were of analytical grade. Dulbecco’s modified
Eagle’s medium (DMEM), penicillin, streptomycin, amphotericin
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B, epidermal growth factor (EGF), insulin, fatty acid free bovine
serum albumin, aprotinin, leupeptin, pepstatin, bestatin, D-
erythro-sphingosine, 3-[4,5-dimethylthiazol-2-yl]2,5-diphenyl
tetrazolium bromide (MTT), Kodak Biomax film, and other
common chemicals were from Sigma Aldrich (St. Louis, MO,
USA). Fetal calf serum (FCS) was from EuroClone (Pero,
Milan, Italy). Basic fibroblast growth factor (bFGF) was
purchased from PeproTech (Rocky Hill, NJ, USA). B27
supplement and DMEM/F12 were obtained from Invitrogen
(Carlsbad, CA, USA). RNeasy mini kit and RNase-free DNAse I
were from Qiagen (Valencia, CA, USA), and iScript cDNA
synthesis kit and SYBR green super mix from Biorad
Laboratories (Hercules, CA, USA). TMZ was from Schering-
Plough (Segrate, Milan, Italy). S1P was from Enzo Life
Sciences (Farmingdale, NY, USA), and the SK inhibitor SKI
from Echelon Biosciences Inc. (Salt Lake City, UT, USA). Goat
anti-MGMT antibody and mouse anti-goat horseradish
peroxidase-linked secondary antibody were from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Rabbit anti-SK1 and
anti-SK2 antibodies were purchased from Abcam (Cambridge,
UK). Goat anti-rabbit horseradish peroxidase-linked secondary
antibody, SuperSignal West Pico and West Femto Maximum
Sensitivity Chemiluminescent Substrate were from Pierce
Chemical Co. (Rockford, IL, USA). [3H]-D-erythro-sphingosine
([3H]-Sph) was purchased from PerkinElmer (Boston, MA,
USA), and [γ-32P] ATP from GE Healthcare (Milan, Italy). High
performance thin layer chromatography (HPTLC) silica gel
plates and all solvents were from Merck (Darmstadt, Germany).
Figure 2.  Effect of TMZ on cell survival.  Representative images of (A) U87-MG and U–SC, and (B) L0627 morphology after 48 h
treatment with vehicle (0.1% DMSO) or 100 µM TMZ (+ TMZ). Images were viewed on a phase contrast microscope, and digital
images were acquired (magnification, 10X; scale bar, 100 µm). (C) U87-MG and U–SC, and (D) L0627 cells were exposed to
different concentrations of TMZ or vehicle. Cell viability was assessed after 48 h of treatment by MTT assay. Results are expressed
as percentage of cell viability with respect to vehicle-treated cells (100%). Data are the mean ± SD of three independent
experiments. * p < 0.05; ** p < 0.01 vs vehicle-treated cells. (E) Cell lysates (60 µg of proteins) were analyzed by immunoblotting
with anti-MGMT and anti-β-actin antibodies. 98G human glioblastoma cell lysates were used as control. The immunoblottings are
representative of one out of three.
doi: 10.1371/journal.pone.0068229.g002
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Cell cultures
U87-MG human glioblastoma multiforme cell line was
obtained from the Istituto Zooprofilattico Sperimentale della
Lombardia e dell’ Emilia (Brescia, Italy) and cultured in DMEM
containing 10% FCS (v/v), 2 mM L-glutamine, 100 units/ml
penicillin, 100 µg/ml streptomycin and 0.25 µg/ml amphotericin
B at 37°C in 5% CO2 humidified atmosphere.
GSCs derived from a human glioblastoma cell line (U–SC)
were isolated in our laboratory from the stable U87-MG cell line
through the use of selective medium composed of DMEM/F12,
supplemented with 10 ng/ml bFGF, 20 ng/ml EGF, 5 µg/ml
insulin, B27 supplement, 2 mM L-glutamine, 100 units/ml
penicillin, 100 µg/ml streptomycin and 0.25 µg/ml amphotericin
B [37–39]. To this purpose U87-MG cells were plated in 100
mm Petri dishes at 3 x 103 cells/cm2 in 5 ml of selective
medium and maintained at 37°C in a humidified atmosphere of
5% CO2 for one month. Every week the medium was replaced
with fresh one, and the cells were counted to follow the
selection process.
GSCs isolated from primary cultures of a human
glioblastoma (L0627) were obtained in the R.G. laboratory from
a post-surgery specimen of a primary human glioblastoma
multiforme as previously reported [39]. L0627 were expanded
in vitro in a selective medium consisting of DMEM/F12, and
supplemented with 10 ng/ml bFGF and 20 ng/ml EGF.
Real-Time PCR
Total RNA was isolated from U87-MG and U–SC cells with
the RNeasy mini kit and treated with the RNase-free DNAse I.
One microgram of RNA was reverse transcribed using the
iScript cDNA synthesis kit according to manufacturer’s
Figure 3.  Expression of sphingosine kinases in U87-MG
and glioma stem cells.  Cell lysates (40 µg of proteins) were
analyzed by immunoblotting with (A) anti-SK1 and anti-GAPDH
antibodies, or (B) anti-SK2 and anti-β-actin antibodies. The
immunoblottings are representative of one out of three.
doi: 10.1371/journal.pone.0068229.g003
instructions. Real-Time PCR was performed using the iQ5
Real-Time PCR detection system (Biorad Laboratories,
Hercules, CA, USA). Specific SYBR green expression assays
(SYBR green super mix) for CD133, nestin and GAPDH were
carried out. Simultaneous amplification of the target sequences
was carried out as follows: 3 minutes at 95°C, 50 cycles 95°C
10 seconds, 58°C 40 seconds, 60°C 10 seconds and 1 cycle
60°C 3 minutes. Results were analyzed using the iQ5 optical
system software (Biorad Laboratories, Hercules, CA, USA).
Relative gene expression was determined using the 2-ΔΔCt
method [40]. Data were normalized to GAPDH expression
(used as endogenous control) and U87-MG cells were used as
calibrator.
Cell treatments
Stock solutions were prepared by dissolving the following
molecules as follows: TMZ and the SK inhibitor (SKI) in DMSO,
and S1P in fatty acid free bovine serum albumin (4 mg/ml in
PBS). Stock solutions were then diluted in fresh medium and
administered to cells for the indicated periods of time. In
parallel, cells were also incubated with vehicles as controls.
Analysis of cell viability
Cell viability was determined by MTT assay. U87-MG and
GSCs were seeded at 104 and 2x104 cells/cm2, respectively.
The day after, cells were treated with different agents for the
indicated periods of time. The medium was then replaced by
MTT dissolved in fresh medium (0.8 mg/ml) for 4 hours. The
formazan crystals were then solubilized in isopropanol/formic
acid (95: 5 v/v) for 10 minutes and the absorbance (570 nm)
was measured using a microplate reader (Wallack Multilabel
Counter, PerkinElmer, Boston, MA, USA).
Immunoblotting
MGMT - For MGMT evaluation, cells were lysed with 20 mM
Tris-Cl pH 8.5, 1 mM EDTA, 5% glycerol, 1 mM β-
mercaptoethanol, 0.1 mM PMSF in ethanol, in presence of
protease inhibitors (10 µg/ml aprotinin, 5 µg/ml leupeptin, 5
µg/ml pepstatin, 3 µg/ml bestatin), as recently described [41].
Cell proteins were resolved by SDS-PAGE on 12%
polyacrylamide gels and transferred onto nitrocellulose
membranes. Membranes were then blocked in 5% milk using
PBS-0,05%Tween 20, incubated for 1 hour with anti-MGMT
primary antibody and finally with a mouse anti-goat horseradish
peroxidase-linked secondary antibody. β-actin was used as
loading control.
SK -For SK evaluation, cells were lysed with 20 mM HEPES
pH 7.4, 50 mM NaCl,1 mM EGTA pH 8.1% Triton X100, 5 mM
β-glycerophosphate, 2 mM sodium orthovanadate, 0.1 mM
sodium pyrophosphate, 1 mM EDTA, in the presence of
protease inhibitors (2 µg/ml each of aprotinin, leupeptin, and
pepstatin). In order to evaluate SK1 expression, cell proteins
were resolved by SDS-PAGE on 10% polyacrylamide gels and
transferred onto nitrocellulose membranes. For SK2
expression, cell proteins were resolved by SDS-PAGE on
12.5% polyacrylamide gels and transferred onto PVDF
membranes. Membranes were then blocked in 5% milk using
TBS-Tween20 0.05%, incubated for 1 hour with anti-SK1, anti-
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SK2 primary antibodies and finally with goat anti-rabbit
horseradish peroxidase-linked secondary antibody. GAPDH or
β-actin were used as loading control. In all cases bound
antibodies were visualized by ECL (SuperSignal West Pico or
West Femto Maximum Sensitivity Chemiluminescent
Substrate), and membranes were exposed to Kodak Biomax
films.
Figure 4.  Biosynthesis and fates of S1P in U87-MG and glioma stem cells.  U87-MG, U–SC and L0627 cells were pulsed with
[3H]-sphingosine (Sph) for the indicated periods of time. At the end, cells and media were processed and analyzed as described in
“Materials and methods”. Panel A, total incorporated radioactivity and intracellular Sph. Panel B, radioactivity associated to total Sph
phosphorylation, total S1P and S1P degradation (3H 2O). Panel C, radioactivity incorporated into intracellular and extracellular S1P.
Data are the mean ± SD of at least three independent experiments.
doi: 10.1371/journal.pone.0068229.g004
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Metabolic studies
Cells were plated on 35 mm dishes in cell culture medium at
5x105 cells/dish. At the time of the experiment, the medium was
gently removed and cells were then pulsed with [3H]-Sph (20
nM, 0.4 µCi/ml) in S1P trapping medium [42]. Subsequently
cells were harvested, total lipids extracted at 4°C with
chloroform/methanol, and partitioned as previously reported
[43]. After centrifugation, the upper alkaline aqueous phase,
containing S1P, was evaporated under a nitrogen stream and
counted for radioactivity by liquid scintillation.
Extracellular S1P was extracted from pulse medium and
partially purified as previously described [19,20]. Briefly a two-
step partitioning was performed, at first in alkaline conditions,
and then a back extraction of the aqueous phase obtained was
carried out in acidic conditions. The final organic phase,
containing S1P, was evaporated under nitrogen stream. The
aqueous phase, containing tritiated water produced from [3H]-
S1P degradation, was purified by fractional distillation and
counted for radioactivity [43]. The fractions containing cellular
and extracellular S1P were submitted to HPTLC on silica gel
plates, using n-butanol/acetic acid/water (3:1:1, v/v/v) as
solvent system. Standard [3H]-S1P was chromatographed on
the same plate, and used as internal standard. At the end of
the chromatography, HPTLC plates were submitted to digital
autoradiography (Beta-Imager 2000, Biospace, Paris, FR), and
S1P was quantified by the beta vision analysis software
(Biospace, Paris, FR).
Figure 5.  Extracellular/intracellular S1P ratio in U87-MG
and glioma stem cells.  U87-MG and both GSC types were
pulsed with 20 nM [3H]-Sph (0.4 µCi/ml) for 30 or 60 minutes.
At the end, S1P was extracted from cells and media and
analyzed as described in “Materials and methods”. The
extracellular/intracellular ratio of S1P-associated radioactivity is
shown, as the mean ± SD of at least three independent
experiments.
doi: 10.1371/journal.pone.0068229.g005
Sphingosine kinase activity in GSC-conditioned
medium
GSCs (5 x 105 cells/dish) were incubated at 37°C in fresh
culture medium for different periods of time (30, 60 min, and 24
h). Media were then collected and concentrated (5000 x g, 1 h
at 4°C). SK activity was then assayed using experimental
conditions known to selectively favour SK1 or SK2 activity, as
previously described [44–46], with some modifications. Briefly,
the reaction mixture contained: concentrated medium (25-50
µl), 25 µM Sph as BSA-complex, 0.5 mM [γ-32P] ATP, 5 mM
MgCl2 and SK buffer (20 mM Tris-Cl pH 7.4, 1 mM EDTA, 0.5
mM deoxypyridoxine, 15 mM NaF, 1 mM β-mercaptoethanol, 1
mM sodium orthovanadate, 40 mM sodium glycerophosphate,
10% glycerol and protease inhibitors) supplemented with either
0.5% Triton X100 (to assess SK1 activity), or 200 mM KCl (to
assess SK2 activity). The mixture was incubated at 37°C for 30
minutes. S1P was then extracted [19] and resolved by HPTLC
on silica gel plates, using 1-butanol/methanol/acetic acid/water
(8:2:1:2, v/v/v/v) as solvent system. At the end of the
chromatography, HPTLC plates were dried and labelled lipids
visualized using autoradiography by overnight exposure to
Kodak Biomax films. The radioactive spots corresponding to
S1P were scraped from the plates, and counted for
radioactivity by liquid scintillation. Background values were
determined in negative controls where Sph was omitted in the
reaction mixture.
Statistical analysis
Results are expressed as means ± SD for at least three
independent experiments. The statistical significance of the
data was determined by the Student’s t-test. Differences were
considered statistically significant at P < 0.05.
Results
Isolation and characterization of GSCs
GSCs were isolated from the human U87-MG glioblastoma
multiforme cell line using a selective growth medium, which
promotes the growth of the stem cell component (U–SC).
Images acquired by phase-contrast microscopy showed
obvious morphological differences between the two cell types
(Figure 1A). U87-MG cells grew adherent to the surface of the
growth support with a fibroblastoid-like morphology,
characterized by the formation of numerous cytoplasmic
extensions. Conversely, U–SC grew in suspension in the
culture medium forming typical aggregates, called
neurospheres, composed of 100-200 cells. It has been
reported that brain tumor-derived cancer stem cells express
high levels of the membrane glycoprotein CD133 and the
cytoskeletal protein nestin [47,48]. In order to assess if the
population of cells obtained by selective isolation was actually
enriched in stem cells, we evaluated the expression of these
stemness markers by real-time PCR. The results show that U–
SC presented a 5.3 and 9.5 fold increase in CD133 and nestin
expression, respectively when compared to U87-MG (Figure
1B). Thus, GSCs obtained from U87-MG are characterized by
stem cells typical morphology and by increased expression of
stemness markers, in agreement with previous reports [47,48].
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As additional in vitro model for GSCs, we exploited L0627,
previously isolated from a post-surgery specimen of a primary
human glioblastoma multiforme. As U–SC, L0627 cells grew in
suspension, efficiently formed neurospheres, and expressed
high levels of the cancer stem cell markers CD133 and the
adhesion molecule CD15, as previously reported [39,49].
Despite the cells’ true stem nature of glioma neurospheres
remains debated, these GSCs reproduce the genotypic and
phenotypic characteristics of glioblastomas more faithfully than
standard glioma cell lines, and are considered an appropriate
model of glioma [39,50].
Survival properties of GSCs: evaluation of TMZ
resistance
In order to analyze cell survival properties, increasing
concentrations of TMZ (ranging from 25 to 200 µM) were used
to treat U87-MG, U–SC and L0627 cells, and the cytotoxic
effect was evaluated. Images obtained by phase contrast
microscopy after 48 hours treatment with 100 µM TMZ showed
that many of U87-MG cells were dead, in suspension, and
those still adherent to the growth surface were strongly
suffering, with a decreased cell size and the loss of normal
fibroblastoid-like morphology (Figure 2A). In contrast, under the
same conditions, U–SC and L0627 cells maintained
unchanged their morphological features, with the typical
formation of neurospheres (Figure 2A, B). These morphological
pieces of evidence were supported by the analysis of cell
viability by MTT assay. As shown in Figure 2C, the treatment
with TMZ decreased U87-MG viability in a concentration-
dependent manner. Indeed the treatment with 100 µM TMZ
was associated with a cell survival of 60%, meanwhile that with
200 µM caused cell death in more than 50% of U87-MG cells.
Conversely, the treatment with TMZ up to 200 µM did not
cause any significant alterations in U–SC vitality (Figure 2C).
Also L0627 viability did not significantly change after treatment
with TMZ at 25-100 µM, the highest TMZ concentration (200
µM) being only partially effective (Figure 2D).
One of the best characterized mechanisms of TMZ
resistance is the increased expression of the DNA repair
protein MGMT [11]; therefore immunoblotting assays of MGMT
were performed. As shown in Figure 2E, MGMT was not
expressed not only in U87-MG, but also in U–SC and L0627.
S1P biosynthesis and fates
An increasing number of evidence demonstrates that S1P
plays an important role as an oncopromoter lipid, involved in
the mechanisms of resistance to chemotherapy in different
tumors, including glioblastoma [26,51]. On this base we first
evaluated the expression of SK1 and SK2, the two known SK
isoforms responsible for S1P synthesis. Immunoblotting assays
demonstrated that U87-MG, U–SC, and L0627 cells all
expressed both SK1 and SK2 (Figure 3).
In order to evaluate S1P production and metabolic fate,
pulse experiments with tritiated Sph were performed. After
short time pulse, the level of incorporated radioactivity was
similar and increased in a time-dependent fashion in all cell
models (Figure 4A). In these conditions, cellular [3H]-Sph
represented less than 5% of the incorporated radioactivity in all
cases, indicating that the cell types were able to rapidly
incorporate and metabolize Sph (Figure 4A). In all cell models,
the radioactivity associated to Sph phosphorylation (as the sum
of S1P and tritiated water, its degradation product) increased
with pulse time (Figure 4B). At all investigated times, tritiated
water represented the bulk of Sph phosphorylation-associated
radioactivity, and increased with pulse times (Figure 4B).
We then analyzed both cells and culture media for their [3H]-
S1P content. As shown in Figure 4C, in U87-MG the levels of
intracellular radioactive S1P increased in a time-dependent
fashion, and about 3% of the radioactivity associated to Sph
phosphorylation was detected extracellularly at both 30 and 60
min of pulse. In both GSC models the radioactivity associated
with intracellular S1P was at least 2-fold lower than in U87-MG
(Figure 4C). Of relevance, the amount of labeled S1P found in
the extracellular milieu of both GSCs was markedly higher than
that of U87-MG (Figure 4C).
Figure 6.  Role of S1P in GSC survival properties.  U–SC (A) and L0627 cells (B) were exposed to 50-200 µM of TMZ alone (♦)
or in combination with 4 µM SKI (●). After 48 hours of treatment, cell viability was assessed by the MTT assay. Results are
expressed as percentage of cell viability with respect to vehicle-treated cells (♦) or cells treated with SKI alone (●) (100%). Data are
the mean ± SD of three independent experiments. * p < 0.05; ** p < 0.01 vs vehicle-treated cells.
doi: 10.1371/journal.pone.0068229.g006
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As shown in Figure 5, the ratio between extracellular and
intracellular S1P was found to be about 10-fold higher in both
GSCs than in U87-MG.
Prompted by these findings, we then hypothesized that the
high amount of S1P retrieved in GSCs medium could be
consequent to SK secretion in the extracellular milieu, as it
occurs in some cell types [44,52,53]. We then evaluated SK1
and 2 activities in cell-conditioned medium. In the used
experimental conditions, the activity of both SK isoforms was
undetectable in the medium from all cell types (data not
shown).
Role of S1P in GSCs survival properties
Stimulated by these results, we then investigated the
possible effect of S1P in GSC sensitivity to TMZ. First, we
evaluated the effect of SK inhibition by administrating the SKI
inhibitor together with TMZ. We found that the co-treatment
with TMZ and SKI (both at sub-toxic concentrations)
significantly reduced cell viability (Figure 6). In particular, in
GSCs treated with TMZ in the presence of SKI, cell viability
was decreased by 70-90%, compared to cells treated with TMZ
alone. Taken together these data indicate that the inhibition of
SKs increases GSC sensitivity to TMZ toxicity, thus reducing
GSC refractoriness to TMZ.
Subsequently, in order to assess the effect of extracellular
S1P in GSC TMZ resistance, we evaluated the effect of
nanomolar concentrations of S1P on cell survival in the
presence of TMZ and SKI, separately or in combination. As
shown in Figure 7, the results of these experiments revealed
that in GSCs the administration of exogenous S1P to control
and TMZ-treated cells significantly increased the number of
viable cells, supporting a growth- and survival-promoting effect
of the phosphorylated Sph. Finally and remarkably, the
treatment with S1P resulted in a 5-fold increase in viable cells,
and thus in the reversion of the toxic effect of SKI-TMZ co-
treatment.
Discussion
In human glioblastomas, the presence of GSCs has been
related to a poor prognosis, and these cells appear the
responsible for glioma recurrences due to their chemo- and
radio-resistance [54,55]. Thus it is conceivable that therapies
targeting this cell population will provide a new approach in the
treatment of glioblastomas. It is in this context that this
research was performed, with the aim to contribute to the
understanding of the pathways crucial for GSC survival
properties, and focusing on the role of S1P as possible survival
mediator in GSCs. We used GSCs isolated either from the
human U87-MG glioblastoma cell line, or from a post-surgery
specimen of a primary human glioblastomas. Despite the
cultured GSC as neurosphere represents an in vitro model of
GSCs, they are recognized as an appropriate model of gliomas
[37–39]. We first obtained evidence that concentrations of TMZ
that were toxic in human U87-MG cells, had no or only limited
effects on GSCs viability. Of relevance, our data demonstrate
that GSCs were resistant to 100-200 µM TMZ, that is to
concentrations higher than those observed in patients
submitted to TMZ chemotherapy. Indeed, in the plasma and
cerebrospinal fluid of glioblastoma patients, the level of this
drug was reported to range from 0.5 to 70 µM, and from 0.8 to
10 µM, respectively [56]. Thus, the used GSC models were
resistant to therapeutic doses of TMZ, in agreement with the
hypothesis that GSCs play a pivotal role in glioblastoma
chemotherapy resistance [5]. Notably, the expression of the
DNA repair protein MGMT, a major contributor to TMZ
resistance [57], was undetectable in both GSC populations,
indicating that mechanisms other than MGMT are involved in
TMZ resistance of these cells.
Further experiments demonstrated that GSCs expressed
both SK isoforms, and pulse studies showed that this cells
were able to efficiently synthesize and degrade S1P, indicating
a very rapid Sph metabolism. The analyses of the pulse media
led us to obtain the major finding of this study, i.e. that GSCs
can rapidly and efficiently produce S1P extracellularly, and thus
can contribute to S1P levels in the extracellular environment. In
particular, extracellular S1P in GSCs was found significantly
higher than in U87-MG, and this difference resulted in an
extracellular/intracellular S1P ratio of about 1:1 in both GSCs,
that is at least 10-fold higher than that of U87-MG. These
findings led us to hypothesize that the relevant amount of S1P
in GSC medium could be consequent to SK secretion in the
extracellular milieu, as it occurs in other cell types [44,52,53].
However, investigations on the SK presence in GSC medium
led us to exclude this hypothesis, and suggest the involvement
of a protein-mediated transport in the S1P export from GSCs.
Figure 7.  Effect of extracellular S1P on GSC resistance to
TMZ.  L0627 cells were exposed to 200 nM S1P, 100 µM TMZ,
and 4 µM SKI, separately or in combination, as indicated.
When used, after 24 hours 200 nM S1P was added again. After
48 hours of treatment, cell viability was measured by the MTT
assay. Results are expressed as percentage of viable cells with
respect to vehicle-treated ones (100%). Data are the mean ±
SD of at least three independent experiments. * p < 0.05; ** p <
0.01 vs vehicle-treated cells.
doi: 10.1371/journal.pone.0068229.g007
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Since different ABC transporters have been implicated in S1P
release [21], it will be of relevance to identify their potential
involvement in the efficient release of S1P into the extracellular
milieu in GSCs. Studies are in progress to identify this
important mechanism.
It has been shown that the up-regulation of the SK isoform
SK1 correlate with shorter survival time of patients with GBM
[28,29]. In addition, other recent studies showed that SK1
inhibition causes apoptosis in TMZ-resistant glioma cells [30].
In spite both SK1 and SK2 were found to be expressed in
GSCs, and these kinases appear to have at least some
overlapping roles, it is tempting to speculate that SK1 might be
involved in the intracellular generation and subsequent release
of S1P in GSC.
The finding that GSCs can export S1P in the extracellular
environment is of relevance for different reasons. First, it is
acknowledged that S1P can act as a potent onco-promoter
molecule in glioblastomas [24,25,33], and GSCs appear to
contribute to the extracellular level of this messenger, thus
favoring tumor progression. Second, emerging pieces of
evidence demonstrate that GSCs do express S1P receptors,
and that S1P administration promotes their proliferation,
migration, and invasivity [35,36], supporting a role of
extracellular S1P in GSC properties. Last, but not least, the
evidence of the efficient production, and extracellular release of
S1P by GSCs implies its role as an autocrine/paracrine signal
of the GSC microenvironment. In this context, it is worth noting
that neural stem cells (NSCs) appear to depend to other cells
for the presence of S1P in their extracellular milieu. Indeed, it
was shown that extracellular S1P is a potent chemo-attractant
messenger in NSCs, but these cells are not able to release
S1P in their external environment [58]. Thus it emerges that,
differently from NSCs, GSCs exhibit the ability to enrich their
extracellular milieu of S1P, representing an important source of
this onco-promoter mediator in the extracellular environment.
The ability of GSCs to release S1P extracellularly is most
likely related to their expression of S1P receptors, and to the
pro-tumor effects of S1P on these cells. In agreement with this
hypothesis, and with the role of S1P as an important
oncopromoter lipid involved in chemotherapy resistance
[18,22,23], we found that S1P plays a key role in GSCs
resistance to TMZ. Indeed we first observed that the inhibition
of S1P biosynthesis, through the SKI inhibitor, made GSCs
sensitive to TMZ. Moreover, exogenous S1P, alone or in
combination with TMZ, was able to revert the cytotoxic effect of
the co-treatment with TMZ and the SKI inhibitor, promoting
GSC survival. It is worth noting that the SKI was effective in
promoting TMZ toxicity even at drug concentrations found in
vivo.
Data from the literature provided evidence that CD133+ cells
are much more responsive to extracellular S1P than are their
parental counterparts, and differential S1P receptor expression
contribute to this feature [35]. Since S1P1 promotes cell
survival, and its expression is increased in CD133+ U87 cells,
as well as in experimental and intracranial glioblastomas [35], it
appears reasonable that S1P1 might be involved in the pro-
survival effect of extracellular S1P in TMZ-treated GSCs. In
support, a recent study [59] published while this work was in
progress reported on the effect on GSC viability of FTY720, a
S1P agonist which bears structural similarity to S1P and binds
to S1P receptors, and its binding induces internalization and
degradation of the S1P1 receptor, resulting in prolonged down-
regulation of this receptor [60]. It was found that in vitro
administration of FTY720 to GSCs decreased cell viability and
acted synergistically with TMZ in promoting cytotoxicity [59]
Moreover, the same study showed that FTY720 decreased
GSCs invasiveness in nude mouse brains and promoted
mouse survival.
In conclusion, this study demonstrates the pivotal role of
extracellular S1P as a mediator of TMZ resistance in GSCs.
Altogether our data implicate, for the first time, GSCs as an
important S1P source in the extracellular microenvironment,
which acts as an autocrine/paracrine signal contributing to their
survival properties. Finally, the data presented herein may
serve useful not only in the study of signal pathways involved in
TMZ-induced apoptosis, but also in the understanding the
possible significance of S1P and its modulators in the
treatment of malignant glial tumors.
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